Acting Chief Financial Officer Daniel Geffken is a proven leader of life science companies with more than 30 years of experience steering strategy, finance and operations across all stages of the corporate life cycle. Also as Co-founder and Managing Director of Danforth Advisors, he leads a team of more than 90 consultants in strategic CFO advisory, accounting and operational support for over 150 clients, ranging from life science start-ups to publicly traded companies with $1 billion+ market capitalizations. He has served as CFO and executive-level advisor to numerous companies, including Apellis Pharmaceuticals, Cabaletta Bio, Cidara Therapeutics, Editas Medicine, Homology Medicines, Promedior, ProMIS Neurosciences and Stealth BioTherapeutics. Over the course of his career, Daniel has raised nearly $2 billion in equity and debt securities for life science companies. Among his pre-Danforth roles, he served as CFO of Transkaryotic Therapies, where he negotiated and closed five equity transactions totaling $600 million – including the largest private placement in biotechnology history at the time. Daniel has been a board member and chairman of audit and compensation committees of both public and private life science companies, including Windtree Therapeutics. He holds a BS from The Wharton School, University of Pennsylvania, and a MBA from Harvard Business School.